SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is trending downwards, driven by concerns around debt financing for new data centers and its association with CoreWeave, which recently reported disappointing earnings, though some argue APLD's fundamentals remain strong. The community is debating whether the stock is oversold and discussing potential catalysts like upcoming earnings and new hyperscaler deals. Investors are closely watching key support levels and analyst price targets amidst a broader sell-off in AI-related stocks.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CRMD is trending due to community discussion around recent earnings and future prospects, with debates focusing on whether the company is undervalued. Despite positive earnings news, some traders express frustration, citing concerns about stock manipulation and the impact of convertible debt. Others remain optimistic, pointing to institutional investments and potential catalysts while closely monitoring TDAPA policy reform.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

CRCL is trending as investors discuss its growth potential amid the evolving stablecoin landscape and upcoming earnings report. Community members are weighing bullish arguments around institutional backing and regulatory tailwinds against concerns about market volatility and potential lock-up expirations. Recent price action and options flow are also key discussion points.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amid renewed discussions around the company's financials and its relationship with figures involved in controversial matters. The community is expressing concerns about potential shareholder dilution and the stock's long-term viability, with some questioning the company's business model. Conversations also touch upon broader political themes and the alignment of the stock with certain ideological viewpoints.

Creative Media & Community Trust Corp. is a real estate investment trust that seeks to own, operate, and develop premier multifamily and creative office assets in vibrant and emerging communities throughout the United States. It operates through the following segments: Office, Hotel, and Lending. The Office segment consists of the rental of office space and other tenant services, including tenant reimbursements, parking, and storage space rental. The Hotel segment involves the operation of hotel properties. The Lending segment focuses on loans to small businesses. The company was founded in 1993 and is headquartered in Dallas, TX.

Creative Media & Community Trust

CMCT is trending due to news of the sale of its lending division, expected to yield $31 million in net proceeds. Bullish traders are eyeing a potential short squeeze given the company's low float and anticipation of a large price increase, while others are wary of the company's debt and the impact on ordinary shareholders.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy ($MSTR) is trending downwards, sparking debate about its correlation with Bitcoin and the effectiveness of its treasury strategy; community members are discussing potential support levels and whether it's oversold, while some express frustration with the stock's performance relative to Bitcoin's price movements and the broader market. Some traders anticipate a short squeeze, while others believe the stock will trade lower.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disney's stock is trending amid anticipation for upcoming earnings, with community members weighing bullish versus bearish scenarios and debating the potential impact of streaming service performance. Discussions also involve Disney's strategic partnerships and content slate, including recent controversies and government shutdowns, influencing investor sentiment. Several analysts are weighing in with price targets and ratings, sparking active speculation on the stock's potential movement.

JD.com, Inc. is a technology-driven E-commerce company, which engages in the sale of electronics products and general merchandise products, including audio, video products, and books. It operates in the following segments: JD Retail, JD Logistics, and New Businesses. The JD Retail segment offers online retail, online marketplace, and marketing services. The JD Logistics segment includes internal and external logistics businesses. The New Businesses segment is composed of JD Property, Jingxi, overseas businesses and technology initiatives. The company was founded on June 18, 1998, by Qiang Dong Liu and is headquartered in Beijing, China.

JD.com Inc - ADR

JD.com is trending as investors anticipate upcoming earnings, with community discussions focusing on expectations and potential market reactions. Some traders point to Singles Day sales data and AI initiatives, while others express frustration with the stock's performance compared to its peers and the broader market. Community members are actively debating whether the stock will beat earnings estimates and if a potential beat will lead to a sustained rally.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor is trending due to upcoming warrant distributions, sparking discussions of a potential short squeeze, while recent insider buying, including the CEO's purchase, signals confidence. The community is closely monitoring the stock's resilience and anticipates a bullish impact from the warrants, focusing on key Fibonacci levels as potential price targets. Traders are also noting positive catalysts related to potential housing policy changes.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

ORCL is facing increased scrutiny due to concerns about its high debt levels and the sustainability of its AI investments, leading to a significant stock decline. Community sentiment is largely negative, with many expressing frustration over the lack of communication from Oracle's management and investor relations. Some investors believe the sell-off is overdone, presenting a buying opportunity, while others fear further downside amid broader worries about an AI bubble.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy

Shares of Tempest Therapeutics (TPST) ended higher on Wednesday amid a broader market rebound on the U.S. pausing tariffs and extended gains after-hours after the company said it was exploring strategic alternatives.&nbsp;The cancer drug developer said its options included a merger, acquisition, partnership, or licensing deal to advance its pipeline and maximize shareholder value.&nbsp;The company has retained MTS Health Partners to assist with the process.CEO Stephen Brady emphasized the company's strong data and regulatory momentum, pointing to Phase 2 results for amezalpat showing a six-month survival benefit in advanced liver cancer and FDA clearance for a pivotal Phase 3 study.&nbsp;However, Brady said capital markets "have been unavailable to support the next stage of advancement."On Stocktwits, sentiment for Tempest surged into the 'extremely bullish' zone from 'neutral' a day ago, accompanied by message volume soaring over 135% in the 24 hours to late Wednesday.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/TPST_sentiment_and_message_volume_April_9_png_4939200400.webp" alt="TPST sentiment and message volume April 9.png" width="1318" height="316"><figcaption>TPST sentiment and message volume April 9. | source: Stocktwits</figcaption></figure>One user said the CEO was "soliciting bidders" through this move following the recent 1-for-13 reverse stock split."Poison pill is still at $25. Now, anyone who wants more than a 10 percent ownership stake can buy whatever they want at $25 or more. Well played, Mr. Brady!" they wrote.<stembedurl>https://stocktwits.com/xyz1232/message/611152790</stembedurl>Another pinned hopes on "well-known" MTS Partners fetching a good merger deal for Tempest. "Even If TPST gets a below-average deal at $360 million, we're still looking at $100 per share."<stembedurl>https://stocktwits.com/GreylockSec/message/611168891</stembedurl>Amezalpat, Tempest's lead candidate, has received both Orphan Drug and Fast Track designations from the FDA.&nbsp;TPST-1495, a dual EP2/EP4 antagonist, is also advancing toward a Phase 2 trial in familial adenomatous polyposis (FAP) with NCI support.<a href="https://stocktwits.com/symbol/TPST">Tempest Therapeutics stock</a> has lost over 34% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Tempest Therapeutics Retail Chatter Explodes As Cancer Drug Developer Mulls Possible Merger

CEO Stephen Brady emphasized the company's strong data and regulatory momentum, pointing to Phase 2 results for amezalpat in advanced liver cancer and FDA clearance for a pivotal Phase 3 study. 

Equity

Why Is Small-Cap Tempest Therapeutics Stock Trading Higher On Thursday?

Tempest Therapeutics receives FDA feedback on the Phase 3 trial design for amezalpat (TPST-1120) in combination with Tecentriq and Avastin to treat first-line hepatocellular carcinoma. Study to begin...

What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?

Tempest Therapeutics shares drop 13% to $2.48 on Thursday despite promising new data from its Phase 1b/2 study. The study shows a six-month survival improvement in hepatocellular carcinoma patients...

Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)

Glancy Prongay & Murray LLP (GPM) announces its investigation of Tempest Therapeutics, Inc. (Nasdaq: TPST) concerning the Company and its directors and officers possible violations of state laws. If...

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

TPST-1120, a first-in-class, oral, selective PPAR antagonist, demonstrates clinical activity in PD-1 inhibitor refractory and immune compromised cancersBased on subsequent positive randomized data...

Tempest Therapeutics, Inc. (NASDAQ:TPST) Expected to Post Q1 2024 Earnings of ($0.36) Per Share

Tempest Therapeutics, Inc. (NASDAQ:TPST  Free Report)  HC Wainwright issued their Q1 2024 earnings estimates for Tempest Therapeutics in a report released on Wednesday, March 20th...

Tempest Therapeutics (NASDAQ:TPST) Stock Rating Reaffirmed by HC Wainwright

Tempest Therapeutics (NASDAQ:TPST  Get Free Report)s stock had its buy rating restated by HC Wainwright in a research report issued to clients and investors on Wednesday...

Tempest Therapeutics (NASDAQ:TPST) Stock Rating Reaffirmed by William Blair

Tempest Therapeutics (NASDAQ:TPST  Get Free Report)s stock had its outperform rating restated by investment analysts at William Blair in a note issued to investors on...

Tempest Reports Year End 2023 Financial Results and Provides Business Update

Announced positive randomized first-line HCC data showing superiority of TPST-1120 combination therapy across multiple study endpoints compared to standard of careReported new biomarker data in two...

Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest Therapeutics was founded in 2011 and is headquartered in Brisbane, CA.

Tempest Therapeutics Inc

Will NVIDIA ($NVDA) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$8.60
Prev Close	$9.62
Open	$9.62
Dividend Yield	0.00%
50-Day Moving Average	$10.31
Beta	2.06
Avg. Volume	42,264.43
PE Ratio	-0.95

52-Week High	$13.65
52-Week Low	$5.35
Market Capitalization	$42.71M
EPS (Annual)	-$19.50
Price to Book	6.73
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

TPST
Tempest Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TPST News

TPSTTempest Therapeutics Inc